RecruitingNCT05561842

Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)

Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

900 participants

Start Date

Sep 21, 2022

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Breast Cancer Female

Summary

The purpose of this study is to train Nigerian radiologists to perform ultrasound-guided breast biopsies. Researchers will use mHealth devices to create a sustainable and practical way of training radiologists in Nigeria to perform and clinically implement US-guided breast biopsies into their practice.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is evaluating a tablet-based mobile ultrasound system for diagnosing breast cancer at the point of care in Nigeria. It compares this portable technology to the standard approach (blind biopsy or surgical removal) to see if it can improve accuracy and access to diagnosis in a low-resource setting. **You may be eligible if...** - You are a female aged 18 or older - A breast ultrasound has found a solid mass that is suspicious for cancer - You would normally require a blind biopsy or surgical removal to get a diagnosis at your hospital **You may NOT be eligible if...** - You are unwilling to sign a consent form - You are under the age of 18 Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREmHealth US-breast biopsy

During this study, women will undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.